VivoSeq
Infectious Disease

Invasive Fungal Infections

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Invasive Fungal Infections is an early-stage landscape with 0 programs across 5 companies. The most active players are Merck & Co., Pfizer, Basilea Pharmaceutica.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBasilea Pharmaceutica logo

Basilea Pharmaceutica

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalF

F2G Biotech GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

22

clinical trials

Completed17 · 77%
Terminated2 · 9%
Withdrawn1 · 5%
Approved for marketing1 · 5%
Available1 · 5%

Clinical Trials

Trial Activity

22 trials

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00015665·40 enrolled
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
Completed·Pfizer logoPfizer·Phase 4·NCT00143312·45 enrolled
Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections
Completed·RRadboud University Medical Center·Phase 4·NCT02805946·21 enrolled
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00034658·336 enrolled
Effect of Administration of Combined Enteral Lactoferrin and Probiotic On Invasive Fungal Infections In Preterm Neonates
Completed·—·Phase 1·NCT05283278·80 enrolled
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02387983·65 enrolled
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001757·20 enrolled
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00418951·120 enrolled
Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01777763·230 enrolled
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00034632
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01075984·279 enrolled
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00034671·98 enrolled
Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT03336502·70 enrolled
An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections
Completed·National Cancer Institute (NCI)·Phase 3·NCT00001810·300 enrolled
Posaconazole to Treat Invasive Fungal Infections
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00033982·50 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)